AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration‐resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first‐line therapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration‐resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first‐line therapy
Authors
Keywords
-
Journal
PROSTATE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-07-11
DOI
10.1002/pros.23875
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis
- (2018) Guangxi Sun et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer
- (2017) Christof Bernemann et al. EUROPEAN UROLOGY
- The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
- (2017) Marzia Del Re et al. EUROPEAN UROLOGY
- Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
- (2017) Trevor M. Penning EXPERT OPINION ON THERAPEUTIC PATENTS
- HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer
- (2017) Daniel Hettel et al. Nature Reviews Urology
- The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation
- (2017) Megan McNamara et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
- (2016) Fangfang Qu et al. CLINICAL CANCER RESEARCH
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer
- (2016) Chengfei Liu et al. MOLECULAR CANCER THERAPEUTICS
- Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer
- (2015) C. Liu et al. CANCER RESEARCH
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression
- (2014) Yuantong Tian et al. Diagnostic Pathology
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
- (2013) Fumio Ishizaki et al. Scientific Reports
- Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
- (2011) Changmeng Cai et al. ENDOCRINE-RELATED CANCER
- In situestrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology
- (2009) Hironobu Sasano et al. PATHOLOGY INTERNATIONAL
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
- (2008) J. A. Locke et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer
- (2007) K Wako et al. JOURNAL OF CLINICAL PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now